CAPAC Members Mark 135th Anniversary of the Chinese Exclusion Act

CAPAC Members Mark 135th Anniversary of the Chinese Exclusion Act

WASHINGTON, D.C. – May 6, 2017 marks the 135th anniversary of the enactment of the Chinese Exclusion Act of 1882, which was the first law to expressly target and prohibit a specific group from immigrating to the United States. The law was signed by President Chester A. Arthur and imposed a ten-year ban on Chinese immigration or naturalization. It was reauthorized and expanded several times in the following decades, and was not repealed until 1943. In 2012, Congress passed a bipartisan resolution introduced by CAPAC Chair Rep. Judy Chu (CA-27), which formally expressed regret for the passage of the Chinese Exclusion Act. To commemorate the 135th anniversary of the Chinese Exclusion Act, CAPAC Members released the following statements:

Congresswoman Judy Chu (CA-27), CAPAC Chair:

“The Chinese Exclusion Act was one of the most discriminatory laws ever passed in our nation’s history, and it left permanent scars on the Chinese American community. It split families apart, created a second-class citizenry, and disenfranchised an entire ethnic community. In fact, my own grandfather who had been here legally since 1904 was forced to carry a certificate of registration at all times for almost 40 years, or risk deportation.

“Unfortunately, 135 years after the Chinese Exclusion Act was signed into law, our nation is once again debating whether an entire group of people should be banned from entering the United States based on their country of origin. This is unacceptable. Now more than ever, we must ensure that policies targeting immigrants, Muslims, and refugees, like President Trump’s un-American Muslim ban, do not succeed. The Chinese Exclusion Act was one of the darkest periods in our nation’s history, and we cannot allow history to repeat itself.”

Congresswoman Grace Meng (NY-06):

“The Chinese Exclusion Act, enacted 135 years ago today, was a dark mark in our in our nation’s history. Steeped in prejudice and bigotry, it was the first law to prevent a specific ethnic group from entering the United States, despite the fact that Chinese laborers made vital contributions to the United States, such as by helping to build the Transcontinental Railroad. Only in 1943 was this law repealed. On the 135th anniversary of this terrible law, may we reflect on our true identity as a nation of immigrants, a nation that does not discriminate based on race, national origin, or religion, a nation that promotes opportunity for all.”

美中生物醫藥協會今日 5/6 慶10週年

轉載

CABA美中生物医药协会2017年会暨十周年庆典召开在即

Original 2017-04-27 Jo Lee CABA

“Boston BioForum 2017”

CABA10th Annual Conference

May 6, 2017

🏨Boston Marriott Newton

📍2345 Commonwealth Ave, Newton, MA 02466

🕙10:00 AM to 6:00 PM on Saturday, May 6, 2017.

SPEAKERS

Gordon Freeman

Gordon J. Freeman, PhD works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School.  Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University. His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cellactivation (B7-2/CD28).

Carmen Bozic, MD

Carmen Bozic MD is Senior Vice President of Global Development at Biogen, accountable for developing, obtaining and maintaining regulatory approval of therapies in Biogen’s therapeutic focus areas of Neurodegenerative and Rare Diseases. Dr. Bozic is an experienced drug development leader with 18 years of progressively increasing responsibilities in the biopharmaceutical industry.

Kenneth I Kaitin, Ph.D.

Dr. Kaitin is Professor of Medicine and Director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. Dr. Kaitin alsoholds appointments as Advisory Professor at Shanghai Medical College of Fudan University in China; Visiting Executive at the Tuck School of Business at Dartmouth College; and faculty of the European Center for Pharmaceutical Medicine at the University of Basel.

Ken LeClair, Ph.D.

Ken LeClair received his undergraduate degree from Bowdoin College and a Ph.D. in Immunobiology from Yale University.

He did a postdoc at the MIT Center for Cancer Research andhad an academic appointment as Assistant Professor of Medicine in theImmunology Division of the Beth Israel Deaconess Medical Center at the Harvard Medical School.

He joined Editas Medicine late in 2016 and is working to help bring CRISPR-based therapies to the clinic and to market.

Samarth Kulkarni, Ph.D.

Samarth(Sam) Kulkarni is the Chief Business Officer of CRISPR Therapeutics since 2015.  At CRISPR, Sam is responsible for Corporate Strategy, Business Development, and Investor Relations. Sam has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. 

Xinyu Weng, Ph.D.

Weng, Xinyu, Ph.D, is First Secretary of the Embassy of the People’s Republic of China to the United States of America. As the primary point of contact for China Food and Drug Administration (CFDA) in the U.S., Dr. Weng is committed to strengthening bilateral food and drug regulatory cooperation between China and the U.S., and reaching out to the U.S. food and drug industry.

Hui Cai, Ph.D.

Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances, and Head of PR and Corporate Communications.

Prior to WuXi, Dr. Cai spent 10 years at Johnson& Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases.

Lynn Yang, MBA

Lynn Yang is focusing on healthcare investment. Prior to joining Sequoia Capital in May, 2015, Lynn worked at Legend Capital healthcare team. Lynn accomplished investment deals in different area of healthcare industry. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product manager at GE Healthcare.  

Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.

Yongzhong Wang, Ph.D.

Dr. Yongzhong Wang is the President of Pharmaceuticals and Executive VP of Simcere Pharmaceutical Group. He manages API manufacturing, sales and international regulatory affairs of the group, as well as Simcere Europe.  Prior to Simcere, Dr. Wang was the CEO of Chengdu Kanghong Biotechnology Co., Ltd, a leading biotech company in China. 

James (Jianguo) Yang, Ph.D.

Dr. James (Jianguo) Yang has over 20-year extensive experience in biopharma industry. Currently, Dr. Yang is President / CEO Abpro-China. Before joining Abpro, Dr. Yang was CSO / VP Biologics in Qilu Pharmaceuticals, and also had scientific leadership positions in Abbott Lab Pharma Division, MedImmune /Astra Zeneca, and Genzyme / Sanofi.

Junzhi (John) Yao, Ph.D.

Dr. Junzhi (John) Yao received his PhD degree in chemistry from Wuhan University. He joined Medicure Inc. in Winnipeg, Canada as a Research Scientist conducting drug discovery research for cardiovascular diseases and stroke.

In 2009, Dr. Yao co-founded TC Scientific Inc. in Edmonton, Alberta, Canada, which has become one of the top CROs in Canada.

Agenda

09:00 - 10:00 am       Registration / Social Networking

10:00 - 10:05 am       Opening Remarks, Kevin Fang, Ph.D., Conference Chair, President-Elect, CABA

10:05 - 10:15 am       Introduction of CABA, Eric Shi, Ph.D., President, CABA

Session I – Novel Therapies for Cancer and Neurological Diseases

SESSION CHAIR:        Lan Cao, Ph.D. and Cindy Yang, MBA.

10:15 - 10:50 am      Samarth Kulkarni, Ph.D., Chief Business Officer, CRISPR Therapeutics.

“CRISPR-based Therapeutics: Making it a Reality in Asian Markets”

10:50 - 11:25 am       Ken LéClair, VP, Technical Development and Manufacturing, Editas Medicine.

“Development of Cell and Gene-Edited Products”

11:25 - 12:00 pm       Carmen Bozic, M.D., SVP Global Develop, Biogen.

“Innovationsin Intrathecal Antisense Oligonucleotide Therapy for Neurological Diseases”

LUNCH AND VENDOR SHOW: 12:00 - 1:30 pm (LunchProvided on Site)

LUNCHEON PRESENTATION

12:45 - 1:05 pm         John Yao, Ph.D., Co-founder and CEO, TC Scientific Inc.

“A CRO’s View of the Pharma Landscape” hosted by Ellen Fan, MSc

SESSION II – Global Innovation, Investment,and Entrepreneurship

SESSION CHAIR: Jian Shao, MBA

1:30 - 2:05 pm    Hui Cai, Ph.D., VP of Corporate Alliances and Head of Communications, WuXi AppTec.

“Platformand Ecosystem for R&D Transformation”

2:05 - 2:40 pm    James Yang, Ph.D., President and CEO, Abpro-China.

“Strategic Partnership for Success in Biologics"

2:40 - 3:15 pm    Yongzhong Wang, Ph.D., President of Pharmaceuticals and Executive VP of Simcere Pharmaceutical Group.

“Innovationsacross the Border, a Personal Journey”

3:15 - 3:50 pm    Lynn Yang, MBA, General Manger, Sequoia Capital “Sequoia China Healthcare Investment Strategy”

3:50 - 4:20 pm    COFFEE BREAK AND VENDOR SHOW

SESSION III - Global Pharma Trends, CFDA Regulatory Reform and Scientific Advancement in PD-1 Research

SESSION CHAIRS: Wendy Yang, MBA and Susan Qu,Ph.D., MBA

4:20 - 4:55 pm    Kenneth Kaitin, Ph.D., Professor and Director, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

“The Global Landscape for Pharmaceutical R&D: Current Trends - Future Opportunities”

4:55 - 5:30 pm    XinYu Weng, Ph.D., MBA, First Secretary of the Embassy of the China to the USA.

“Overview of CFDA Drug Regulatory Reform”

5:30 - 6:05 pm    Gordon Freeman, Dana-Farber Cancer Institute, Professor, Medicine, Harvard Medical School.

"PD-1Cancer Immunotherapy"

6:05 - 6:10 pm    Closing Remarks

6:10 - 8:30 pm    10th Anniversary Evening Celebration

Key Feature: Former Presidents’ Documentary Film

6:50 - 7:50 pm    Dinner

7:50 - 8:30 pm    Performances

Registration

Link: http://caba-annualmeeting-2017.eventdove.com（请复制此链接并在浏览器中打开）

也可点击文末“阅读原文”或长按以下图片提取二维码直达注册页面。

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.

Chinese-American BioMedical Association

CITY TO HOST OPEN DATA CHALLENGE SHOWCASE

CITY TO HOST OPEN DATA CHALLENGE SHOWCASE

BOSTON - Friday, May 5, 2017 - This Saturday, the City of Boston's Department of Innovation and Technology (DoIT) will host the Analyze Boston Open Data Challenge Showcase. The showcase is the culminating event of the two-year effort to build the next generation of Boston's open data program. Hosted by DoIT's Analytics Team, the Open Data Challenge participants will present projects that fit into one of five challenge tracks: Reducing Boston's Carbon Footprint, Making Open Data Local, Learning More from BuildBPS Data, Identifying Fire Risks or Telling a Story Through Data. This Open Data showcase is free and open to members of the public. Interested attendees are asked to register online. WHEN:       9 a.m. to 5 p.m.                    Saturday, May 6, 2017 WHERE:    District Hall                   75 Northern Ave. WHO:        Andrew Therriault, Boston's Chief Data Officer                         Presenters from:                         Boston Fire Department                         Boston Public Library                         Dudley Street Neighborhood Initiative                         National Fire Protection Association

Boston Public Schools to Partner with Boston Big Picture School to Reimagine 7-12 Learning

Boston Public Schools to Partner with Boston Big Picture School to Reimagine 7-12 Learning

Funding and management assistance from NewSchools Venture Fund will fuel efforts to launch new, innovative school models

Boston - Friday, May 5, 2017 - Boston Public Schools Superintendent Tommy Chang is proud to announce a partnership with Boston Big Picture School to launch the development of a new, innovative school model that will incorporate personalized student learning plans that build off the student's passions and the integration of real-world problem solving through internships. Boston Big Picture School is a part of the Big Picture Learning Network, a Rhode Island-based educational nonprofit that provides a framework for school design and support to schools that are seeking to rethink the way they educate students. The initiative was selected as one of 29 organizations to receive financial grants this year from NewSchools Venture Fund. In addition to the funding, NewSchools will provide management assistance and create a forum for sharing best practices among the grant recipients. As part of its commitment, Big Picture Learning will work closely with the Boston Public Schools (BPS) to design an innovative school model that creates an academic setting that meets all students where they are, helps them succeed, and inspires them to create a brighter future. The initiative will be integrated with other BPS planning processes, such as BuildBPS, the district's 10-year educational and facilities master plan, and the district's work to redesign the high-school learning experience to better prepare BPS students for college, career and lifelong success. "Boston is a city of innovation across many sectors. In teaming up with BPS, Boston Big Picture School will help bring new innovation to the education of our children and provide them with 21st century skills to flourish in our city," said Mayor Martin J. Walsh. "Its concepts will help inform decisions around school-building investments as we continue to implement BuildBPS." Boston Big Picture School will focus on designing a school that will serve BPS students in grades 7-12. In its model, students will pursue a personalized academic program rooted in his or her unique curiosity, passion and goals. Through a range of project based learning, internships and blended learning experiences they will acquire the necessary knowledge and skills to gain access to competitive colleges and careers. "Last year, Big Picture Learning had an opportunity to present to the Boston School Committee its visions for an innovative school that would transform how children are taught," said School Committee Chairperson Michael O'Neill. "We are interested to see this project further develop into a new school archetype that could dramatically improve the educational outcomes of our children." Superintendent Chang said he looks forward to collaborating with Boston Big Picture School to develop a new school design that could help reimagine how children learn. "The instructional model that it is developing could reinvent education as we know it," Dr. Chang said. "It will foster relationship building between students, advisors and families; promote individualized learning by identifying student's passions, goals and needs; and promote 21st century skills by providing work-based learning." Boston Big Picture School will also establish and nurture a culture of trust, respect, equality, and empowerment so that all members of the community are learning and valued as we build a community rooted in democratic values. The design team for the Boston Big Picture School is being lead by Kevin Brill, the associate headmaster of Fenway High School who has worked as a teacher and administrator in the Boston Public Schools for over 20 years. "Boston Big Picture School is excited to be selected as a member of the 2017 'invent cohort' by NewSchools Venture Fund and to partner with the Boston Public Schools and Big Picture Learning in developing a school model that will provide a unique choice for students within the city of Boston," Brill said. NewSchools Venture Fund is funding projects like Boston Big Picture School as part of a movement to rethink education in the 21st century. "Too many of today's schools were built for a different time and purpose," said Scott Benson, managing partner at NewSchools Venture Fund. "We believe schools can be reimagined to better prepare young people for the future. That's why NewSchools is proud to invest in these teams of educators who are thinking boldly and creating new opportunities to set students up for success, regardless of where they're from." "We at Big Picture Learning are thrilled to bring our experience to bear in support of Boston Big Picture School's innovative new school design," added Andrew Frishman, Co-Executive Director of Big Picture Learning. "This school model, like those all across our national and international network, will have at its core the local needs of the vibrant community it serves. We're excited for what's next."

STATEMENT OF ATTORNEY GENERAL MAURA HEALEY ON THE HOUSE PASSAGE OF THE AMERICAN HEALTH CARE ACT

STATEMENT OF ATTORNEY GENERAL MAURA HEALEY ON THE HOUSE PASSAGE OF THE AMERICAN HEALTH CARE ACT

BOSTON – Today, Attorney General Maura Healey issued the following statement:

“In Massachusetts, we believe that everyone should have access to health care. Clearly President Trump and Speaker Ryan disagree. The Republican bill would make it harder for sick people to access treatment and for healthy people to stay well. It would jeopardize access to reproductive health care for women. And in the midst of the national opioid epidemic, it would cut vital addiction and mental health services. The House has ignored the concerns of health care experts, doctors, nurses, and the millions of Americans who depend on the Affordable Care Act. I urge the U.S. Senate to reject this bill.”